The Ministry of Health of the Russian Federation has updated its clinical guidelines for the diagnosis and treatment of acute respiratory viral infections (ARVI) in adults. The document was prepared by the Russian Scientific Medical Society of Therapists in collaboration with the V.I. Pokrovsky National Association of Specialists in Infectious Diseases and reflects modern approaches to pharmacotherapy and the prevention of complications.
A key change is the update to the drug treatment section. During medical treatment, patients with ARVI symptoms are now recommended to use drugs with oxyethylammonium methylphenoxyacetate (e.g., Trekrezan®) and azoximer bromide. Kagocel has been excluded from the list, reflecting a revision of its clinical appropriateness. Bacterial lysates have also been included for immunostimulation in uncomplicated forms of ARVI.
Trekrezan® (oxyethylammonium methylphenoxyacetate), which has a dual immunomodulatory and adaptogenic effect, has been officially included in the list of recommended agents for the prevention and treatment of ARVI. The drug stimulates the production of interferons, activates the immune system, and restores strength after illness.
For acute bronchitis, to accelerate the expectoration of sputum, the regulator recommends using Ingasalin® solution, a hypertonic solution with hyaluronic acid for inhalation. The drug has a triple mechanism of complex action on the pathogenesis of cough (protects lung tissue, thins and removes sputum).
«The changes in the recommendations prove that medicine is moving forward and increasingly relies on proven data. It is important for us that our drugs, produced to high-quality standards, receive recognition at the level of official documents, help doctors and patients, and improve people's quality of life», reported the Solopharm press center.
The updated recommendations reflect current clinical experience and are aimed at improving the quality of therapy and patient safety.
Media Contacts: press@grotexmed.com
Solopharm Press Service
